06Sep 2023
SGLT2 Inhibitors Show Promise in Treating Lupus Nephritis

SGLT2 Inhibitors Show Promise in Treating Lupus Nephritis

A recent study has shed light on the potential benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in treating renal issues in patients with type 2 diabetes. A study applied empagliflozin treatment to lupus-prone MRL/lpr mice, uncovering encouraging results. Empagliflozin significantly reduced anti-dsDNA IgG-specific antibodies, serum creatinine, and proteinuria in these mice and mitigated renal damage. Human biopsy samples also revealed increased SGLT2 expression in lupus nephritis patients. The study suggests that SGLT2 inhibitors could provide non-immunosuppressive therapy for lupus nephritis and other autoimmune kidney diseases, offering hope for improved renal function.

  • #rheumatology

Like

Save

Share